Latest Rare diseases Stories
Input will help shape the role of public contributions to orphan drug approvals OTTAWA, Aug.
A nine-year study recently released proves the need TOWSON, Md., Aug.
SAN FRANCISCO, Aug.
In her new role, Sharon will focus on advocating for and supporting MSA families as well as on educating healthcare professionals unfamiliar with this rare neurological disorder. La
In his new role, Dr.
Acceptance of Regulatory Submission Triggers $10 Million Milestone Payment to Auxilium CHESTERBROOK, Pa., July 31, 2014 /PRNewswire/ --
LEXINGTON, Mass., July 30, 2014 /PRNewswire/ -- Synageva BioPharma Corp. ("Synageva") (NASDAQ: GEVA), a biopharmaceutical
LifeScienceIndustryResearch.com adds “Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014” to its store.
ArmaGen to Receive up to Approximately $225 Million Including Initial Upfront Payment of $15 Million in Cash and Equity, an Additional Equity Investment, R&D Funding, Development and Sales Milestones,
- Neurotrope enters into world-wide, exclusive license agreement with Mount Sinai; Files related provisional patent for Bryostatin-1 - PLANTATION, Fla., July 22, 2014 /PRNewswire/